[go: up one dir, main page]

CN114015776A - Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy - Google Patents

Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy Download PDF

Info

Publication number
CN114015776A
CN114015776A CN202111357697.4A CN202111357697A CN114015776A CN 114015776 A CN114015776 A CN 114015776A CN 202111357697 A CN202111357697 A CN 202111357697A CN 114015776 A CN114015776 A CN 114015776A
Authority
CN
China
Prior art keywords
mir
lung adenocarcinoma
platinum
mirna
sensitivity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202111357697.4A
Other languages
Chinese (zh)
Inventor
杨承刚
范冰燕
郭静
李雨晨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Yangshen Biomedical Co Ltd
Original Assignee
Qingdao Yangshen Biomedical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao Yangshen Biomedical Co Ltd filed Critical Qingdao Yangshen Biomedical Co Ltd
Priority to CN202111357697.4A priority Critical patent/CN114015776A/en
Publication of CN114015776A publication Critical patent/CN114015776A/en
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Data Mining & Analysis (AREA)
  • Primary Health Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Databases & Information Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Oncology (AREA)
  • Evolutionary Computation (AREA)
  • Bioethics (AREA)

Abstract

The miRNA comprises miR-4291, miR-449a and/or miR-663, and the miRNA is proved by experiments to be a marker for predicting the sensitivity of lung adenocarcinoma to platinum-containing double-drug chemotherapy, so that the miRNA has higher diagnosis efficiency, can assist a clinician in judging the sensitivity or reactivity of a subject to platinum-containing double-drug chemotherapy, and further screens out lung adenocarcinoma patients sensitive to platinum-containing double-drug chemotherapy to realize individual treatment.

Description

Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy.
Background
Lung cancer (Lung cancer) is the most common malignancy with the highest incidence and mortality worldwide, among which Non-small cell Lung cancer (Non-small cell Lung cancer, NSCLC) accounts for 80%, while Lung adenocarcinoma (Lung adenocarinoma) is the major histological type of NSCLC (Ji P, Diedirichs S, Wang W, et al MALAT-1, alpha novel Non-coding RNA, and thymosin beta 4 precursor tumor and subvalin early-stage-small cell Lung cancer [ J ]. Oncogene,2003,22(39): 8031-8041.). Although The related research and clinical trials on lung cancer are rapidly progressed, The prognosis of lung cancer is still poor, 80-85% of patients are diagnosed in middle and advanced stages, and The 5-year survival rate is less than 15% (Bailey-Wilson J E, Amos C I, Pinney S M, et al. A major lung cancer survival probability loci maps to chromosome 6q 23-25 [ J ]. The American Journal of Human Genetics,2004,75(3):460 plus 474.), therefore, in order to achieve early diagnosis and accurate and individual treatment of lung cancer patients, a new biomarker and an action target point need to be screened, The action mechanism of lung cancer development is researched, and The survival rate of The lung cancer patients is improved.
miRNA is a non-coding single-stranded RNA with a length of 19-22 nucleotides. They act by silencing mRNA, thereby regulating gene expression at the post-transcriptional level. The synthesis of miRNA is that pre-miRNA is firstly transcribed from miRNA coding gene, and then pri-miRNA is cut into hairpin pre-miRNA with length of about 80bp by RNase III family member Drosha, and the pre-miRNA is also miRNA precursor. Finally, pre-miRNA is processed in the cytoplasm to double stranded RNA by RNase iii family member Dicer. One of them is combined with an RNA-silencing complex (RISC) to form a RISC-miRNA complex, and then is combined again to the 3' UTR of mRNA of a target gene to regulate a target. With the recent gradual popularization and deepening of bioinformatics in the field of miRNA, scientists apply bioinformatics software to analyze the mechanism of miRNA, and show that a plurality of miRNA regulation targets are located on tumor regulation factors or pathways closely related to cell canceration, which has important significance for the research of tumor etiology. However, the current analysis of lung adenocarcinoma is mostly limited to the prediction of target genes.
At present, the conventional methods for treating lung adenocarcinoma comprise operation treatment, platinum-containing dual-drug chemotherapy, radiotherapy, targeted therapy and the like, wherein, platinum-containing double-drug chemotherapy is concerned as a treatment scheme of advanced lung adenocarcinoma, and is a treatment scheme which is widely applied to patients with advanced lung adenocarcinoma clinically, the platinum-containing double-drug chemotherapy refers to the combined application of platinum-type chemotherapeutic drugs (carboplatin and cisplatin) and other non-platinum single drugs (paclitaxel, gemcitabine and vinorelbine), however, it is still difficult to predict which lung adenocarcinoma patients will be sensitive to platinum-containing dual-drug chemotherapy treatment regimens, and predicting the sensitivity or responsiveness of lung adenocarcinoma patients to platinum-containing dual-drug chemotherapy remains a significant challenge, therefore, the biomarker which can be used for accurately predicting the sensitivity of the lung adenocarcinoma to the platinum-containing dual-drug chemotherapy is found, and the application of the compound in the screening of lung adenocarcinoma patients before chemotherapy is of great significance to the field.
Disclosure of Invention
In order to overcome the technical problems existing in the prior art, the invention aims to provide application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides application of a reagent for detecting the expression level of miRNA markers in a sample in preparing a product for predicting sensitivity or responsiveness of lung adenocarcinoma to platinum-containing dual-drug chemotherapy.
Further, the miRNA marker is miR-4291, miR-449a and/or miR-663.
The sequence of the miR-4291 is shown as SEQ ID NO 1;
UUCAGCAGGAACAGCU(SEQ ID NO:1)
the sequence of the miR-449a is shown as SEQ ID NO. 2;
UGGCAGUGUAUUGUUAGCUGGU(SEQ ID NO:2)
the sequence of the miR-663 is shown as SEQ ID NO. 3;
AGGCGGGGCGCCGCGGGACCGC(SEQ ID NO:3)
further, the miRNA markers are miRNAs of which miR-4291, miR-449a and/or miR-663 are all human sources (hsa).
Further, the agent is selected from:
a probe that specifically recognizes the miRNA marker; or
A primer that specifically amplifies the miRNA marker.
Further, the platinum-containing dual-drug chemotherapy treatment regimen comprises carboplatin + paclitaxel, cisplatin + gemcitabine, cisplatin + vinorelbine, carboplatin + gemcitabine.
Further, the product comprises a reagent for detecting the expression level of the miRNA marker in the sample by a high-throughput sequencing method, real-time quantitative PCR, RT-PCR, in-situ hybridization and a chip.
Furthermore, the high-throughput sequencing method comprises first-generation sequencing, second-generation sequencing and third-generation sequencing, wherein the first-generation sequencing is also called Sanger sequencing and is a sequencing technology utilizing DNA polymerase synthesis reaction, and the first-generation sequencing is a sequencing technology based on the Sanger method; the second generation sequencing is based on massively parallel sequencing technology (MPS), and can simultaneously complete the synthesis of a complementary strand of a sequencing template and the acquisition of sequence data; the third generation sequencing is based on single molecule sequencing and massively parallel sequencing technology.
Further, the real-time quantitative PCR as referred to in the present invention refers to a real-time quantitative polymerase chain reaction, PCR generally employs a plurality of cycles of denaturation, annealing of primer pairs to opposite strands, and primer extension to exponentially increase the copy number of a target nucleic acid sequence; RT-PCR, which is referred to herein as reverse transcription-polymerase chain reaction, uses reverse transcriptase to prepare complementary DNA (cDNA) from mRNA, and the cDNA is then amplified by PCR to produce multiple copies of the DNA.
Further, the in situ hybridization in the present invention refers to a process of hybridizing specifically labeled nucleic acids with known sequences as probes with nucleic acids in cells or tissue sections, thereby performing accurate quantitative localization of specific nucleic acid sequences, and the in situ hybridization can be performed on cell samples or tissue samples.
Further, the chip detection in the present invention refers to gene chip detection, also called DNA chip detection or biochip detection, which refers to fixing a large number of probe molecules on a support, hybridizing with a labeled sample, and analyzing the sequence and number of target molecules by detecting the intensity and distribution of hybridization signals.
Further, the sample is derived from blood or tissue of the subject.
In a second aspect of the invention, there is provided a product for predicting the sensitivity or responsiveness of a patient with lung adenocarcinoma to platinum-containing dual drug chemotherapy.
Further, the product comprises a reagent for detecting the expression level of miRNA markers in the sample, wherein the miRNA markers are miR-4291, miR-449a and/or miR-663.
Further, the agent is selected from:
a probe that specifically recognizes the miRNA marker; or
A primer that specifically amplifies the miRNA marker.
Further, the product comprises a kit, a chip or test paper.
Further, the primers contained in the kit for specifically amplifying the miRNA marker may be prepared by chemical synthesis, appropriately designed with reference to known information by using a method well known to those skilled in the art, and prepared by chemical synthesis.
In certain embodiments, the kit is marketed, distributed or sold as a unit for performing the methods of the invention. Such kits may comprise carrier means compartmentalized to receive, in close confinement, one or more container means (e.g., vials, tubes, etc.), each container means comprising one of the separate components to be used in the method. For example, one of the container means may comprise a probe that carries or can carry a detectable label. Such probes may be polynucleotides specific for polynucleotides of one or more genes comprising gene expression characteristics. Where the kit utilizes nucleic acid hybridization to detect a target nucleic acid, the kit can also have a container containing one or more nucleic acids for amplifying the target nucleic acid sequence and/or a container containing a reporter means.
Further, the kit will generally comprise the above-described container and one or more additional containers containing commercially and user-desired materials, including buffers, diluents, filters, needles, syringes, and package inserts containing instructions for use. A label may be present on the container to indicate the particular application of the composition, and may also indicate the direction of in vivo or in vitro use, such as those described above. Other optional components of the kit include one or more buffers (e.g., blocking buffer, wash buffer, substrate buffer, etc.), other reagents (e.g., substrate chemically altered by enzymatic labeling), epitope retrieval solutions, control samples (positive and/or negative controls), control sections, and the like.
In a third aspect of the invention, a pharmaceutical composition for increasing the sensitivity or responsiveness of a patient with lung adenocarcinoma to platinum-containing dual-drug chemotherapy is provided.
Further, the pharmaceutical composition comprises an agent for reducing the expression level of miR-4291, an agent for reducing the expression level of miR-449a and/or an agent for increasing the expression level of miR-663.
Further, the pharmaceutical composition also comprises a pharmaceutically acceptable carrier and/or an auxiliary material.
Furthermore, the pharmaceutical composition of the present invention can be prepared into various dosage forms according to requirements. Including but not limited to: tablets, solutions, granules, patches, ointments, capsules, aerosols or suppositories for transdermal, mucosal, nasal, buccal, sublingual or oral use.
Further, the route of administration of the pharmaceutical composition of the present invention is not limited, including but not limited to: intravenous, intraperitoneal, intraocular, intraarterial, intrapulmonary, oral, intravesicular, intramuscular, intratracheal, subcutaneous, transdermal, pleural, topical, inhalation, transmucosal, cutaneous, gastrointestinal, intraarticular, intraventricular, rectal, vaginal, intracranial, intraurethral, intrahepatic, intratumoral. In some cases, the administration may be systemic. In some cases topical administration.
Further, the dosage of the pharmaceutical composition of the present invention is not limited as long as the desired effect is obtained, and may be appropriately determined depending on the symptoms, sex, age, and the like.
The fourth aspect of the invention provides application of miRNA markers miR-4291, miR-449a and/or miR-663 in construction of a calculation model or a system embedded with the calculation model for predicting sensitivity or reactivity of a lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy.
Further, the calculation model takes the expression levels of miRNA markers miR-4291, miR-449a and/or miR-663 as input variables, and carries out operation through a bioinformatics method, so as to output the sensitivity or reactivity of the lung adenocarcinoma patient to platinum-containing double-drug chemotherapy.
A fifth aspect of the invention provides a system or apparatus for predicting the sensitivity or responsiveness of a patient with lung adenocarcinoma to platinum-containing dual-drug chemotherapy;
further, the system or apparatus comprises:
(1) an evaluation device: comprises a control unit and a storage unit, and is used for predicting and evaluating the sensitivity or the responsiveness of a lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy;
(2) information communication terminal apparatuses communicatively connected to each other: for providing data on the expression level of the miRNA markers miR-4291, miR-449a, and/or miR-663 in a sample from a patient with lung adenocarcinoma;
the control unit of the evaluation device comprises the following four units:
1) a data receiving unit: for receiving data transmitted from the information communication terminal device regarding the expression level of the miRNA marker in a sample from a lung adenocarcinoma patient;
2) a discrimination value calculation unit: which calculates a discrimination value based on discrimination of the expression level of the miRNA marker received by the data receiving unit and the expression level of the miRNA marker stored in the storage unit as an explanatory variable;
3) discrimination value criterion evaluation unit: evaluating the sensitivity or reactivity of the lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy based on the discrimination value calculated by the discrimination value calculation unit;
4) an evaluation result transmitting unit: which transmits the result of the predictive evaluation of the lung adenocarcinoma patient obtained by the discrimination value criterion evaluation unit to the information communication terminal device.
In order to further clarify the content of the present invention, some of the scientific terms referred to in the present invention are explained as follows.
In the context of the present invention, the term "miRNA marker", as well as "marker", "biomarker", refers to an indicator of a patient's phenotype, in particular embodiments of the present invention, to a marker that is differentially expressed between lung adenocarcinoma patients (responders) sensitive or responsive to platinum-containing dual drug chemotherapy and lung adenocarcinoma patients (non-responders) non-sensitive or responsive to platinum-containing dual drug chemotherapy, including, but not limited to: genes, proteins, small molecule metabolites, carbohydrates, glycolipid-based molecules, etc., preferably, the marker is a miRNA.
In the context of the present invention, the term "expression level", as well as "expression level of a miRNA marker" or "expression level of a biomarker", refers to the expression level of a miRNA according to the present invention in a sample.
In the context of the present invention, the term "sample", as well as "sample", "subject sample", "sample of a lung adenocarcinoma patient", refers to a composition obtained or derived from a subject of interest (lung adenocarcinoma patient) comprising cellular entities and/or other molecular entities to be characterized and/or identified, e.g. on the basis of physical, biochemical, chemical and/or physiological characteristics. The sample may be obtained from blood of a subject (lung adenocarcinoma patient) and other fluid samples of biological origin and tissue samples, such as biopsy tissue samples or tissue cultures or cells derived therefrom. The source of the tissue sample may be solid tissue, such as from a fresh, frozen and/or preserved organ or tissue sample, biopsy tissue or aspirate; blood or any blood component; a body fluid; cells from any time of pregnancy or development of the individual; or plasma. The term "sample" includes a biological sample that has been treated in any way after it has been obtained, e.g., by treatment with a reagent, stabilization, or enrichment for certain components (e.g., proteins or polynucleotides), or embedded in a semi-solid or solid matrix for sectioning purposes. Samples described in the present invention include, but are not limited to: tissue, whole blood, blood-derived cells, serum, plasma, lymph, synovial fluid, cell extracts and combinations thereof, preferably, the sample is a tissue.
In the context of the present invention, the term "primer", as well as "amplification primer", refers to a nucleic acid fragment comprising 5-100 nucleotides, preferably said primer or amplification primer comprises 15-30 nucleotides capable of initiating an enzymatic reaction (e.g., an enzymatic amplification reaction).
In the context of the present invention, the term "probe" refers to a nucleic acid sequence comprising at least 5 nucleotides, e.g.comprising 5 to 100 nucleotides, which probe is capable of hybridizing under the specified conditions with the expression product of the target gene or with the amplification product of this expression product to form a complex. The hybridization probes may also include labels for detection. Such labels include, but are not limited to, labels for fluorescent quantitative PCR or fluorescent in situ hybridization.
In the context of the present invention, the term "area under the working characteristic curve (AUC) of a subject" is an indicator of the performance or accuracy of a diagnostic procedure. The accuracy of a diagnostic method is best described by its Receiver Operating Characteristics (ROC). ROC plots are line graphs of all sensitivity/specificity pairs derived from continuously varying decision thresholds across the entire data range observed. In a specific embodiment of the present invention, the diagnostic efficacy of the miRNA marker of the present invention for predicting the sensitivity or reactivity of a patient with lung adenocarcinoma to platinum-containing dual-drug chemotherapy can be evaluated according to the area under the working characteristic curve (AUC) of the subject, wherein if the AUC > 0.6, it indicates that the miRNA marker has a certain diagnostic efficacy, and the miRNA marker can be used as a marker for predicting the sensitivity or reactivity of a patient with lung adenocarcinoma to platinum-containing dual-drug chemotherapy; if the AUC is greater than 0.7, the miRNA marker has relatively good diagnostic efficacy and can be used as a marker for predicting the sensitivity or the reactivity of a lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy; if the AUC is greater than 0.8, the miRNA marker has better diagnostic efficacy and can be used as a marker for predicting the sensitivity or the responsiveness of a lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy.
In the context of the present invention, the term "responsive" refers to a patient/subject having, suspected of having, or predisposed to having lung adenocarcinoma showing a response to a platinum-containing dual-drug chemotherapeutic treatment regimen. The skilled person will readily determine whether a patient/subject undergoing platinum-containing dual drug chemotherapy will show a response in accordance with the methods described herein.
In the context of the present invention, the term "sensitive" refers to a patient/subject having, suspected of having, or predisposed to having lung adenocarcinoma that shows a positive response to a platinum-containing dual-drug chemotherapeutic treatment regimen in some way. One skilled in the art will readily determine whether a patient/subject undergoing a platinum-containing dual-drug chemotherapy regimen will exhibit a response in accordance with the methods described herein.
Compared with the prior art, the invention has the advantages and beneficial effects that:
the genes miR-4291, miR-449a and/or miR-663 are combined for predicting the sensitivity or reactivity of a patient with lung adenocarcinoma to platinum-containing double-drug chemotherapy, the accuracy, sensitivity, specificity and AUC value are high, a clinician can be assisted in judging the sensitivity or reactivity of a subject to the platinum-containing double-drug chemotherapy, and then the patient with lung adenocarcinoma sensitive to the platinum-containing double-drug chemotherapy is screened out to realize individual treatment.
Drawings
Embodiments of the invention are described in detail below with reference to the attached drawing figures, wherein:
FIG. 1 is a graph showing the results of miR-4291 differential expression between patients with lung adenocarcinoma in the group responsive to platinum-containing dual-drug chemotherapy and the group non-responsive to platinum-containing dual-drug chemotherapy;
FIG. 2 is a graph showing the results of miR-449a differential expression between patients with lung adenocarcinoma who responded to platinum-containing dual-drug chemotherapy and patients who did not respond to platinum-containing dual-drug chemotherapy;
FIG. 3 is a graph showing the results of miR-663 differentially expressed between patients with lung adenocarcinoma in the group responsive to platinum-containing dual-drug chemotherapy and the group non-responsive to platinum-containing dual-drug chemotherapy;
FIG. 4 is a graph showing the results of miR-4291 for predicting the diagnostic efficacy of lung adenocarcinoma sensitivity to platinum-containing dual-drug chemotherapy;
FIG. 5 is a graph showing the results of miR-449a on predicting the diagnostic efficacy of lung adenocarcinoma sensitivity to platinum-containing dual-drug chemotherapy;
FIG. 6 is a graph showing the results of miR-663 in predicting the diagnostic efficacy of lung adenocarcinoma sensitivity to platinum-containing dual-drug chemotherapy;
FIG. 7 is a graph showing the results of miR-4291+ miR-449a on predicting the diagnostic efficacy of lung adenocarcinoma sensitivity to platinum-containing dual-drug chemotherapy;
FIG. 8 is a graph showing the results of miR-4291+ miR-663 for predicting the diagnostic efficacy of lung adenocarcinoma sensitivity to platinum-containing dual-drug chemotherapy;
FIG. 9 shows a graph of the results of miR-449a + miR-663 for predicting the diagnostic efficacy of lung adenocarcinoma sensitivity to platinum-containing dual-drug chemotherapy;
FIG. 10 shows a result graph of the diagnostic efficacy of miR-4291+ miR-449a + miR-663 on predicting lung adenocarcinoma sensitivity to platinum-containing dual-drug chemotherapy.
Detailed Description
The present invention is further illustrated by the following examples, which should be construed as being merely illustrative and not limitative of the remainder of the disclosure. As will be understood by those of ordinary skill in the art: various changes, modifications, substitutions and alterations can be made to the embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the claims and their equivalents. The following examples are examples of experimental methods not indicating specific conditions, and the detection is usually carried out according to conventional conditions or according to the conditions recommended by the manufacturers. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs, and any methods and materials similar or equivalent to those described herein may be applied.
Example 1 Gene screening related to susceptibility of Lung adenocarcinoma to platinum-containing Dual-drug chemotherapy
1. Data source
Before patients with pathologically diagnosed lung adenocarcinoma receive platinum-containing dual-drug chemotherapy, tumor tissues of the patients are collected, and the lung adenocarcinoma patients are divided into a response group (R, responder) or a non-response group (NR, non-responder) according to whether the lung adenocarcinoma is responsive to the platinum-containing dual-drug chemotherapy or not in combination with RECIST (standard for evaluating the curative effect of solid tumors); the lung adenocarcinoma patients do not receive platinum-based drug chemotherapy before receiving platinum-containing dual-drug chemotherapy; the response group comprises patients with lung adenocarcinoma with Complete Response (CR) and patients with lung adenocarcinoma with Partial Response (PR), and the non-response group comprises patients with Stable Disease (SD) and Progressive Disease (PD); data from this study were derived from GSE56264, non-responder: responder-24: 16;
further, in this study, the platinum-containing dual-drug chemotherapy regimen for patients with lung adenocarcinoma included carboplatin + paclitaxel, cisplatin + gemcitabine, cisplatin + vinorelbine, carboplatin + gemcitabine;
comparing the miRNAs differentially expressed between the lung adenocarcinoma patients in the responsive group and the lung adenocarcinoma patients in the non-responsive group; differential expression analysis was performed using the "limma" package in the R language, where the screening criteria for differentially expressed genes was p<0.05，|log2FC|>1。
2. Results of the experiment
The results show that 43 genes are differentially expressed between the response group and the non-response group obtained by screening, wherein miR-4291, miR-449a and miR-663 show significant differential expression between patients with lung adenocarcinoma who respond to platinum-containing dual-drug chemotherapy and patients who do not respond to platinum-containing dual-drug chemotherapy, and the expression trends of miR-4291, miR-449a and miR-663 in the response group are respectively down-regulated, down-regulated and up-regulated (see fig. 1-3), and the results indicate that miR-4291, miR-449a and miR-663 are potential biomarkers for predicting the sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy.
Example 2 application of differential expression gene obtained by screening in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy
1. Experimental methods
Performing Receiver Operating Characteristic (ROC) analysis on the genes screened in example 1 and differentially expressed between the response group and the non-response group using R comprising "pROC" (version 1.15.0), and calculating the area under the operating characteristic curve (AUC) of the subject to evaluate the accuracy of a single differentially expressed gene, any two differentially expressed gene combinations, and three differentially expressed gene combinations, respectively, for predicting the sensitivity of lung adenocarcinoma to platinum-containing dual drug chemotherapy, wherein the AUC values range from 0 to 1;
wherein, when judging the diagnosis effectiveness of the single differential expression gene on predicting the sensitivity of the lung adenocarcinoma to the platinum-containing dual-drug chemotherapy, the expression quantity of the single differential expression gene is directly adopted for analysis, the level corresponding to the one point with the maximum Youden index is selected as the cutoff value, and the differential expression gene with the AUC of 0.5< AUC <0.8 is used for joint analysis;
when the diagnosis effectiveness of the combination of any two differential expression genes and the combination of three differential expression genes on the prediction of the sensitivity of the lung adenocarcinoma to the platinum-containing dual-drug chemotherapy is judged, Logitics regression analysis is carried out on the expression level of each differential expression gene, the probability of each lung adenocarcinoma individual on the sensitivity of the platinum-containing dual-drug chemotherapy is calculated through a fitted regression curve, different probability division threshold values are determined, and the accuracy, the specificity, the sensitivity and the like of the combination of any two differential expression genes and the combination of three differential expression genes on the prediction of the sensitivity of the lung adenocarcinoma to the platinum-containing dual-drug chemotherapy are calculated according to the determined probability division threshold values.
2. Results of the experiment
The results show that the gene combination miR-4291+ miR-449a, miR-4291+ miR-663, miR-449a + miR-663 and miR-4291+ miR-449a + miR-663 has diagnosis efficiency remarkably superior to that of a single gene for predicting the sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy, and the genes are combined to predict that the sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy has higher AUC values (see table 1 and figure 4-figure 10), which shows that the genes miR-4291, miR-449a and/or miR-663 can be used for clinically assisting doctors to judge the sensitivity of lung adenocarcinoma patients to platinum-containing dual-drug chemotherapy, and has very good clinical application prospect.
Diagnostic efficacy of the genes of Table 1 for predicting susceptibility of lung adenocarcinoma to platinum-containing dual-drug chemotherapy
Gene AUC value
miR-4291 0.701
miR-449a 0.690
miR-663 0.768
miR-4291+miR-449a 0.758
miR-4291+miR-663 0.872
miR-449a+miR-663 0.849
miR-4291+miR-449a+miR-663 0.911
The above description of the embodiments is only intended to illustrate the method of the invention and its core idea. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made to the present invention, and these improvements and modifications will also fall into the protection scope of the claims of the present invention.
Sequence listing
<110> the Qingdao is dependent on deep-age biomedical GmbH
Application of <120> miRNA in prediction of sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy
<141> 2021-11-16
<160> 3
<170> SIPOSequenceListing 1.0
<210> 1
<211> 16
<212> RNA
<213> Homo sapiens
<400> 1
uucagcagga acagcu 16
<210> 2
<211> 22
<212> RNA
<213> Homo sapiens
<400> 2
uggcagugua uuguuagcug gu 22
<210> 3
<211> 22
<212> RNA
<213> Homo sapiens
<400> 3
aggcggggcg ccgcgggacc gc 22

Claims (10)

1. Application of a reagent for detecting the expression level of a miRNA marker in a sample in preparation of a product for predicting sensitivity or reactivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy is characterized in that the miRNA marker is miR-4291, miR-449a and/or miR-663.
2. The use according to claim 1, wherein the agent is selected from the group consisting of:
a probe that specifically recognizes the miRNA marker; or
A primer that specifically amplifies the miRNA marker.
3. The use of claim 1, wherein the product comprises reagents for detecting the expression level of the miRNA marker in a sample by high-throughput sequencing methods, real-time quantitative PCR, RT-PCR, in situ hybridization, or chip.
4. The use of claim 1, wherein the sample is derived from blood or tissue of a subject.
5. A product for predicting sensitivity or reactivity of a patient with lung adenocarcinoma to platinum-containing dual-drug chemotherapy, which comprises a reagent for detecting the expression level of miRNA markers in a sample, wherein the miRNA markers are miR-4291, miR-449a and/or miR-663.
6. The product according to claim 5, wherein the agent is selected from the group consisting of:
a probe that specifically recognizes the miRNA marker; or
A primer that specifically amplifies the miRNA marker.
7. The product of claim 5, wherein the product comprises a kit, chip, or strip.
8. A pharmaceutical composition for improving sensitivity or reactivity of a patient with lung adenocarcinoma to platinum-containing dual-drug chemotherapy, which is characterized by comprising an agent for reducing the expression level of miR-4291, an agent for reducing the expression level of miR-449a and/or an agent for increasing the expression level of miR-663.
The application of miRNA markers miR-4291, miR-449a and/or miR-663 in constructing a calculation model for predicting sensitivity or reactivity of a lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy or a system embedded with the calculation model;
the calculation model takes the expression levels of miRNA markers miR-4291, miR-449a and/or miR-663 as input variables, and outputs the sensitivity or reactivity of the lung adenocarcinoma patient to platinum-containing double-drug chemotherapy through operation by a bioinformatics method.
10. A system or apparatus for predicting the sensitivity or responsiveness of a lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy, said system or apparatus comprising:
(1) an evaluation device: comprises a control unit and a storage unit, and is used for predicting and evaluating the sensitivity or the responsiveness of a lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy;
(2) information communication terminal apparatuses communicatively connected to each other: for providing data on the expression level of the miRNA markers miR-4291, miR-449a, and/or miR-663 in a sample from a patient with lung adenocarcinoma;
the control unit of the evaluation device comprises the following four units:
1) a data receiving unit: for receiving data transmitted from the information communication terminal device regarding the expression level of the miRNA marker in a sample from a lung adenocarcinoma patient;
2) a discrimination value calculation unit: which calculates a discrimination value based on discrimination of the expression level of the miRNA marker received by the data receiving unit and the expression level of the miRNA marker stored in the storage unit as an explanatory variable;
3) discrimination value criterion evaluation unit: evaluating the sensitivity or reactivity of the lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy based on the discrimination value calculated by the discrimination value calculation unit;
4) an evaluation result transmitting unit: which transmits the result of the predictive evaluation of the lung adenocarcinoma patient obtained by the discrimination value criterion evaluation unit to the information communication terminal device.
CN202111357697.4A 2021-11-16 2021-11-16 Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy Withdrawn CN114015776A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111357697.4A CN114015776A (en) 2021-11-16 2021-11-16 Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111357697.4A CN114015776A (en) 2021-11-16 2021-11-16 Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy

Publications (1)

Publication Number Publication Date
CN114015776A true CN114015776A (en) 2022-02-08

Family

ID=80065031

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111357697.4A Withdrawn CN114015776A (en) 2021-11-16 2021-11-16 Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy

Country Status (1)

Country Link
CN (1) CN114015776A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115449552A (en) * 2022-09-01 2022-12-09 浙江医院 Drug treatment lung cancer sensitivity related gene and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115449552A (en) * 2022-09-01 2022-12-09 浙江医院 Drug treatment lung cancer sensitivity related gene and application thereof

Similar Documents

Publication Publication Date Title
CN111961725B (en) Kit or device for detecting pancreatic cancer and detection method
US20200370127A1 (en) Biomarkers in Peripheral Blood Mononuclear Cells for Diagnosing or Detecting Lung Cancers
JP6203209B2 (en) Plasma microRNA for detection of early colorectal cancer
CN113832232A (en) Biomarker for predicting responsiveness of lung adenocarcinoma to platinum-containing dual-drug chemotherapy, and related product
US20180142303A1 (en) Methods and compositions for diagnosing or detecting lung cancers
EP2800820A1 (en) Methods and kits for detecting subjects at risk of having cancer
CN108949992B (en) Biomarker related to esophageal squamous carcinoma and grading thereof
AU2017281099A1 (en) Compositions and methods for diagnosing lung cancers using gene expression profiles
CN101851682B (en) MiRNA combination used for detecting esophageal squamous cell carcinoma and application thereof
US20230265523A1 (en) Molecular marker for early pancreatic neoplasm detection, detection method and use thereof
CN110229899B (en) Plasma marker combinations for early diagnosis or prognosis prediction of colorectal cancer
CN108588226A (en) Detect the miRNA combination of breast cancer patients with brain transfer and the kit containing the combination
CN111187840B (en) Biomarker for early breast cancer diagnosis
CN107299129B (en) Application of circulating nucleic acid as breast cancer biomarker
CN108866187B (en) Long-chain non-coding RNA marker related to lung cancer auxiliary diagnosis and application thereof
CN114015776A (en) Application of miRNA in predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy
CN113862369A (en) Marker related to sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy and application thereof
CN113862367A (en) MiRNA-based prediction of sensitivity of lung adenocarcinoma patient to platinum-containing dual-drug chemotherapy
CN116987791B (en) Application of plasma markers in identification of benign and malignant thyroid nodule
CN112063714A (en) miRNA related to colorectal cancer and application thereof
CN113981089A (en) Method for predicting sensitivity of lung adenocarcinoma to platinum-containing dual-drug chemotherapy
CN113981088A (en) Application of miRNA marker and related product thereof in predicting sensitivity of lung adenocarcinoma to chemotherapy
CN114032308A (en) Use of FAM83A, KPNA2, KRT6A and LDHA in combination as a biomarker for lung adenocarcinoma
CN103589786B (en) Method, test kit and the primer of detection RRM1 mRNA relative expression quantity and probe
CN109182514B (en) Lung cancer diagnosis or metastasis diagnosis marker LncRNA Loc729658 and kit and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220208